Research-use catalog page
COA request, lot visibility, availability, and schema stay aligned.
The 2X Blend combines CJC-1295 Without DAC and Ipamorelin — the standard GHRH+GHRP research combination producing synergistic, selective GH pulse amplification through two independent receptor systems.
Currently unavailable
This product is listed for research reference. It is not currently available for ordering. Live alternatives from the same research category are shown below.
This product is listed for research reference and is not currently available for ordering. See live alternatives below or contact the team.
Notify me when availableNeed the COA before you order? Request it here.
In your order
Lyophilized vial
Sterile-filtered, freeze-dried peptide in glass vial, sealed under inert gas.
Lot ID on every vial
Printed lot ID ties this exact vial to its analytical record.
COA on request
Independent third-party HPLC certificate, matched to your lot, sent on request.
Carrier-tracked shipping
Shipped from a US facility with full carrier tracking and protective packaging.
The Peptific standard
Peptide quality is invisible until it isn’t. Lot identity, purity, fill integrity, and chain of custody are the difference between usable research material and wasted budget.
Third-party HPLC tested
Every lot is tested for identity and purity by an independent analytical lab. Certificate of Analysis available on request, tied to the exact lot you receive.
Lyophilized and lot-tracked
Sterile-filtered, freeze-dried, sealed under inert gas. Each vial carries its own lot ID — full chain of custody from fill to delivery.
US-based fulfillment
Orders ship from a temperature-controlled US facility with carrier tracking. No drop-shipping, no opaque overseas relay.
Real support, not a ticket queue
A real person responds to research questions, lot questions, and order questions — usually same business day. No bot triage.
How it works
CJC-1295 Without DAC activates GHRH receptors (somatotrope priming, pulse amplitude baseline); Ipamorelin activates GHS-R1a (pulse magnitude amplification) — two mechanistically independent receptor pathways. Combined, they produce synergistic GH release greater than either alone. Ipamorelin's GH selectivity (no cortisol/prolactin co-stimulation) keeps the GH endpoint clean for research interpretation.
Compound profile
Product definition
The 2X Blend combines CJC-1295 Without DAC and Ipamorelin — the standard GHRH+GHRP research combination producing synergistic, selective GH pulse amplification through two independent receptor systems.
The 2X Blend is a pre-combined formulation of CJC-1295 Without DAC (MOD GRF 1-29) and Ipamorelin designed for the standard GHRH+GHRP pulsatile GH research protocol. The combination reflects the convergence of two independent lines of GH axis pharmacology research: GRHH receptor pharmacology: GHRH analogs (CJC-1295 Without DAC) act on the GHRH receptor to increase somatotrope responsiveness and the available pool of GH ready for release per pulse. GH secretagogue receptor pharmacology: GHRPs (Ipamorelin) act on GHS-R1a to trigger GH release directly through a calcium-signaling pathway, independent of GHRH receptor input. When both receptor systems are activated simultaneously, the resulting GH pulse is significantly larger than either system alone — a synergistic effect documented in rodent GH pulse studies. The 2X Blend pre-combines these compounds in a single lyophilized vial to reduce preparation complexity for labs running this standard research protocol. Ipamorelin's selection as the GHRP component (versus GHRP-2 or GHRP-6) is deliberate: its GH selectivity profile keeps the combination's endpoint attributable to GH-axis effects, maintaining research interpretability when the study endpoint is downstream GH or IGF-1 signaling rather than broad pituitary hormone secretagogue pharmacology.
Research audience
The 2X Blend is used by researchers studying GH pulse amplitude pharmacology, GHRH+GHRP synergistic mechanisms, pituitary somatotrope biology, GH axis dose-response relationships, and GH-dependent downstream signaling (IGF-1, anabolic pathway). It is the appropriate combination when selective pulsatile GH research is the protocol objective.
Research context
The GHRH+GHRP combination protocol emerged from the observation that GHRH and GHRP activate GH release through pharmacologically independent pathways that produce additive or synergistic effects. Early characterization in rodent models showed that simultaneous GHRH + GHRP-6 administration produced GH pulses larger than either compound alone, establishing the synergy principle. Subsequent research confirmed the synergy across multiple GHRH and GHRP compound combinations. The selection of ipamorelin as the optimal GHRP partner for this combination protocol came from comparative selectivity studies (discussed in the ipamorelin product description): ipamorelin produces equivalent or superior GH release to GHRP-2 and GHRP-6 with dramatically lower cortisol and prolactin co-stimulation. In GH axis research where the downstream endpoint is GH-specific effects (IGF-1, muscle protein synthesis markers, body composition), the absence of cortisol confounders in ipamorelin-containing protocols produces cleaner, more interpretable results. The 2X Blend designation reflects both compounds' presence in a single preparation. In research protocol design, the key variable to titrate is the dose of each component and the administration frequency relative to the study endpoint — the pre-combined format ensures consistent dose ratios across protocol timepoints.
Common questions
Research Use Only
Sold for laboratory and research purposes only. Not approved for, nor intended for, human or veterinary consumption, diagnostic use, or therapeutic application. These products have not been evaluated by the Food and Drug Administration. Keep out of reach of children. For use by qualified researchers only.
Nothing on this page constitutes medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare provider before making any health or treatment decisions.
By accessing this product page you confirm that you are a qualified researcher aged 18 or older and that you will use this product solely for lawful laboratory research purposes. View Research Use Policy
This product is listed for research reference and is not currently available for ordering. See live alternatives below or contact the team.
Notify me when availableAvailable now
These products from the same research category are currently available for ordering.
You might also want to check out these products.
CJC-1295 Without DAC
CJC-1295 Without DAC (MOD GRF 1-29) is a tetrasubstituted GHRH(1-29) analog with ~30-minute half-life — the preferred short-acting GHRH analog for pulsatile GH research protocols, commonly paired with ipamorelin.
CJC-1295 With DAC
CJC-1295 With DAC is a long-acting GHRH analog with albumin-binding modification that sustains elevated GH and IGF-1 for 6–8 days per administration in preclinical and early clinical research.
GHRP-6 Acetate
GHRP-6 is a hexapeptide GHS-R1a agonist and the founding GHRP compound — studied in preclinical models for GH release, significant appetite stimulation, and cortisol co-stimulation via ghrelin receptor activation.
Ipamorelin
Ipamorelin is a selective pentapeptide GHRP studied in preclinical models for GH release without cortisol or prolactin elevation — the most selective GHRP in its class.
IGF-1LR3
IGF-1 LR3 is an 83-amino-acid IGF-1 analog with reduced IGFBP binding, extending half-life from ~15 minutes to ~20–30 hours — the most studied long-acting IGF-1 analog in preclinical research.
Hexarelin Acetate
Hexarelin (Examorelin) is the most potent characterized GHRP hexapeptide — GHS-R1a agonist with Phase II human data and unique CD36 cardiac receptor binding providing GH-independent cardioprotection in animal models.
IGF-DES
Tesamorelin
Tesamorelin is a 44-amino-acid GHRH analog with N-terminal trans-3-hexenoic acid modification — the only FDA-approved GHRH peptide, validated in Phase III trials for visceral adiposity reduction.
Sermorelin
Sermorelin is a 29-amino-acid synthetic GHRH(1-29) analog — the first FDA-approved GHRH peptide (Geref), with the longest published research history of any synthetic GHRH compound.
MOD GRF 1-29
MOD GRF 1-29 (CJC-1295 Without DAC) is a tetrasubstituted GHRH(1-29) analog with ~30-minute half-life — the most commonly used short-acting GHRH compound for pulsatile GH secretion research.
GHRP-2
GHRP-2 (Pralmorelin) is a synthetic hexapeptide GHS-R1a agonist approved in Japan for GH stimulation testing — a potent non-selective GHRP that stimulates GH alongside cortisol and prolactin.
$25.00
$12.00
$30.00
$29.00